Current HER2-targeted therapies in early-stage breast cancer Several clinical trials have shown that HER2-targeted agents have significantly impacted the long-term outcomes and disease-free survival of patients with HER2-positive early-stage breast cancer. Here, ERBB2 is linked to breast carcinoma.